Fluoxymesterone Therapy in Advanced Breast Cancer
Abstract
ANDROGENIC hormones have been effectively employed in the therapy of advanced breast cancer. Objective improvement occurs in approximately 25 per cent of patients with osseous metastases, with a lower rate of response in patients with soft-tissue lesions.1 Since the effects of castration in premenopausal women are far superior to those of androgenic therapy, the male hormones have been employed primarily for women of postmenopausal age. A continuing search for more effective androgenic compounds is under way. Testosterone propionate, administered intramuscularly in three divided doses of 150 to 300 mg. weekly, has become the standard agent in the evaluation by comparison . . .
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Androgens such as testosterone propionate, fluoxymesterone, and calusterone used in adjuvant therapy of breast cancer have an efficacy comparable to that achieved with other types of endocrine manipulations.
“well recognized observations have shown that androgens such as testosterone propionate (162, 167-169), fluoxymesterone (170, 171), and calusterone (172) used in the adjuvant therapy of breast cancer have an efficacy comparable to that achieved with other types of endocrine manipulations (165,169,173,174).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [170]
Many studies have confirmed beneficial effects of androgens on breast cancer.
“Many studies subsequently confirmed the beneficial effects of androgens on breast cancer (165, 167-174, 251, 252).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [170]
Cites
Increased Erythropoiesis Induced by Androgenic-Hormone Therapy
Kennedy, B. J., & Gilbertsen, A. S. (1957) · New England Journal of Medicine · doi:10.1056/nejm195704182561601 · Cited by 145 · see citing works
Self-citationEFFECTS OF INTENSIVE SEX STEROID HORMONE THERAPY IN ADVANCED BREAST CANCER
Kennedy, B. J. (1953) · JAMA · doi:10.1001/jama.1953.63690120004013 · Cited by 95 · see citing works
Self-citationSYNTHESIS OF POTENT ORAL ANABOLIC-ANDROGENIC STEROIDS
Herr, M., Hogg, J. A., & Levin, R. H. (1956) · Journal of the American Chemical Society · doi:10.1021/ja01583a072 · Cited by 38 · see citing works
COUNCIL ON PHARMACY AND CHEMISTRY
(1951) · JAMA · doi:10.1001/jama.1951.03670050053011 · Cited by 23 · see citing works
Antitumorigenic and tumor-stimulating actions of steroid hormones
Iglesias, R. (1957) · Cancer · doi:10.1002/1097-0142(195707/08)10:4 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · see citing works
Poulin, R., Baker, D., & Labrie, F. (1988) · Breast Cancer Research and Treatment · doi:10.1007/bf01805942 · Cited by 172 · see citing works
Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland.
Sourla, A., Martel, C., Labrie, C., & Labrie, F. (1998) · Endocrinology · doi:10.1210/endo.139.2.5762 · Cited by 49 · see citing works
Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat.
Dauvois, S., Li, S., Martel, C., & Labrie, F. (1989) · Breast Cancer Research and Treatment · doi:10.1007/bf01806301 · Cited by 47 · see citing works
Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., & Labrie, F. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.772 · Cited by 38 · see citing works
Labrie, F., Li, S., B�langer, A., C�t�, J., M�rand, Y., & Lepage, M. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665803 · Cited by 18 · see citing works
- Authors
- Kennedy, B. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Kennedy, B. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1958-10-02
- Volume
- 259
- Issue
- 14
- Pages
- 673-675
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003271123
- Cited by
- 100
- References
- 5
- Citations by year
- 2026: 3 · 2024: 5 · 2023: 7 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 7 · 2016: 7 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Keywords
- fluoxymesterone, advanced breast cancer, androgenic hormones, bone metastasis, soft tissue metastasis, postmenopausal women, testosterone propionate, castration
- MeSH terms
- Breast, Breast Neoplasms, Fludrocortisone, Fluoxymesterone, Humans, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
